In the third quarter of 2024, AC Immune reported significant progress in its pipeline, highlighted by the advancement of its ACI-7104.056 VacSYn Phase 2 trial for Parkinson’s disease and a CHF 24.6 ...

In a report released today, Trevor Williams from Jefferies maintained a Buy rating on ACI Worldwide (ACIW – Research Report), with a price target of $68.00. The company’s shares closed yesterday at ...